Vanderbilt University

P Jeffrey Conn

Craig William Lindsley

Darren W Engers

Colleen M Niswender

Carrie K Jones

Andrew S Felts

Julie L Engers

Corey R Hopkins

Kyle A Emmitte

Shaun R Stauffer

Michael R Wood

Bruce J Melancon

Charles David Weaver

Sean R Bollinger

Susana Conde-Ceide

Aaron M Bender

Alice L Rodriguez

José Manuel Bartolomé-Nebreda

Michael Steven Poslusney

Paul K Spearing

James M Salovich

Kayla J Temple

Rocco D Gogliotti

James C Tarr

Madeline Long

Richard Williams

Gregor James MacDonald

Yiu-Yin Cheung

Han Min Tong

Katrina A Bollinger

Douglas J Sheffler

Brittney S Bates

Rory A Capstick

Logan A Baker

Alison R Gregro

Thomas M Bridges

José Ignacio Andrés-Gil

Manuel Jesús Alcázar-Vaca

Changho Han

Joe Panarese

Joseph David Panarese

Jason Manka

Ya Zhou

Yong-Jin Wu

Thomas Bachgaard Jensen

Brian A Chauder

Anna E Ringuette

Joanne Bronson

Miguel Angel Pena-Piñón

Gregor McDonald

José Manuel Bartolome-Nebreda

Jon Jacobs

Katrina A Smith

Anna L Blobaum

Manuel Jesus Alcazar Vaca

María Luz Martín-Martín

Matthew Spock

Megan M Breiner

Gregor Macdonald

Chrysa Malosh

Evan P Lebois

Eric S Dawson

Patrick R Gentry

Gregor James Macdonald

Leah C Konkol

Jason Guernon

Jerri M Rook

Melissa A Korkmaz-Vaisys

Michael S Poslusney

Disclosed herein are analogues of 6-(4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidin-1-yl)-[1,2,4]triazolo[4,3-b]pyridazine, i.e. 7-(4-((phenyl or pyridin-3-yl)oxy)piperidin-1-yl)-4H-pyrimido[1,2-b]pyridazin-4-one derivatives of formula (I) which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Substituted pyrimido[1,2-b]pyridazines as positive allosteric modulators of the muscarinic acetylcholine receptor M4

Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

Antagonists of the muscarinic acetylcholine receptor M4

Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.

Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Disclosed herein are analogues of 6-(4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidin-1 -yl)-[1,2,4]triazolo[4,3-b]pyridazine of formula (Ib), which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Substituted pyrimido[1,2-b]pyridazines as positive allosteric modulators of the muscarinic acetylcholine receptor M

Described are positive allosteric modulators of muscarinic acetylcholine receptor M(mAChR M), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.

Positive allosteric modulators of the muscarinic acetylcholine receptor M

Antagonists of the muscarinic acetylcholine receptor M

Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Disclosed herein are 3-azabicyclo[3.1.0]hexan-6-amine compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.

Disclosed herein are tricyclic compounds, including 3-(difluoromethyl)-4-methylpyrimido[4',5&#x2032;:4,5]thieno[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

Positive allosteric modulators of the muscarinic acetylcholine receptor M4

Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds of formula (Ia), which may be useful as antagonists of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions. 

Disclosed herein are substituted 2-azaspiro[3.3]heptane compounds of formula (I'), which may be useful as antagonists of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions. 

Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction. 

Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Isoquinoline amine compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Disclosed herein are octahydropyrrolo[3,4-b]pyrrole compounds of formula (I), which may be useful as antagonists of the muscarinic acetylcholine receptor M(mAChR M). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions. 

Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4

Growing community of inventors

Brentwood, TN, United States of America

P Jeffrey Conn